HEMOLENS DIAGNOSTICS
to keep you going
to keep you going
HMoleNS Diagnostics aims to revolutionize cardiac diagnostics and make a significant impact on global healthcare. By addressing the shortcomings of current diagnostic pathways, the company offers a promising solution to the widespread issue of inaccurate diagnosis and unnecessary invasive procedures in identifying atherosclerosis. Founded in 2015 and based in Poland, the team comprising bioengineers, cardiologists, and ICT professionals has developed an innovative, non-invasive method to detect coronary artery disease. With the potential to save lives and reduce healthcare costs, HMoleNS Diagnostics is poised to attract substantial interest from investors seeking to support groundbreaking solutions in the medical industry. The company's dedication to advancing cardiac care aligns with the growing demand for innovative technologies in the healthcare sector, making it a compelling opportunity for venture capital investment.
There is no investment information
No recent news or press coverage available for HEMOLENS DIAGNOSTICS.
We care about your data, and we'd love to use cookies make your experience better.